FOXJ2

Across TCGA pan-cancer cohorts, FOXJ2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FOXJ2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FOXJ2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FOXJ2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

HNSC, UCEC, and BLCA are the cancer types where FOXJ2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.190	0.601	.024	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.412	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FOXJ2–HNSC (OS)

Open the HNSC breakdown →